logo
KORENG
logo
- 바이넥스
- 바이오의약품 CDMO
- 합성의약품
- 투자정보
- 윤리경영
- 채용정보
투자정보
- 바이넥스
- 바이오의약품 CDMO
- 합성의약품
- 투자정보
- 윤리경영
- 채용정보
재무정보
- 전자공시
- 전자공고
- 재무정보
- 주식정보
- 내부정보관리규정
바이넥스의 재무정보를 안내해 드립니다.
Statement of Financial Position(Unit: KRW, x1,000,000)
| Account subject | 39th term (2024.12) | 38th term (2023.12) | 37th term (2022.12) |
|---|---|---|---|
| Current asset | 90,323 | 70,492 | 104,869 |
| Non-current asset | 188,760 | 185,234 | 195,787 |
| Total asset | 279,083 | 255,726 | 300,657 |
| Current liabilities | 91,994 | 67,358 | 98,245 |
| Non-current liabilities | 5,538 | 8,176 | 7,863 |
| Total liabilities | 97,532 | 75,534 | 106,108 |
| Capital stock | 16,342 | 15,881 | 15,881 |
| Capital surplus | 163,213 | 135,817 | 135,817 |
| Other capital surplus | -5,235 | -5,235 | -5,235 |
| Accumulated other comprehensive income | -8,567 | -6,490 | 3,329 |
| Retained earnings | 14,798 | 40,220 | 44,757 |
| Total capital | 181,551 | 180,192 | 194,549 |
Income statement(Unit: KRW, x1,000,000)
| Account subject | 39th term2024.01.01 ~ 2024.12.31 | 38th term2023.01.01 ~ 2023.12.31 | 37th term2022.01.01 ~ 2022.12.31 |
|---|---|---|---|
| Sales revenue | 130,046 | 154,825 | 156,665 |
| Operating profit | -29,571 | 2,055 | 18,040 |
| Sales revenue operating profit margin | -22.74% | 1.33% | 11.52% |
| Profit before income tax expenses | -38,249 | -4,224 | 16,025 |
| Net profit for the year | -34,500 | -4,537 | 13,157 |
| Sales revenue net profit margin | -26.53% | -2.93% | 8.40% |
Statement of Financial Position(Unit: KRW, x1,000,000)
| Account subject | 39th term (2024.12) | 38th term (2023.12) | 37th term (2022.12) |
|---|---|---|---|
| Current asset | 92,571 | 73,694 | 108,952 |
| Non-current asset | 186,817 | 183,317 | 189,410 |
| Total asset | 279,388 | 257,011 | 298,410 |
| Current liabilities | 92,219 | 67,443 | 98,264 |
| Non-current liabilities | 5,562 | 8,243 | 7,863 |
| Total liabilities | 97,781 | 75,685 | 106,127 |
| Capital stock | 16,342 | 15,881 | 15,881 |
| Capital surplus | 163,974 | 135,602 | 135,602 |
| Other capital surplus | -5,612 | -5,235 | -5,235 |
| Accumulated other comprehensive income | -14,049 | -11,640 | 3,329 |
| Retained earnings | 20,706 | 46,700 | 42,029 |
| 비지배지분 | 246 | 18 | 677 |
| Total capital | 181,607 | 181,325 | 192,283 |
Income statement(Unit: KRW, x1,000,000)
| Account subject | 39th term2024.01.01 ~ 2024.12.31 | 38th term2023.01.01 ~ 2023.12.31 | 37th term2022.01.01 ~ 2022.12.31 |
|---|---|---|---|
| Sales revenue | 130,051 | 156,677 | 134,399 |
| Operating profit | -30,755 | 17,179 | 13,109 |
| Sales revenue operating profit margin | -23.65% | 10.96% | 9.75% |
| Profit before income tax expenses | -38,927 | 15,234 | 24,234 |
| Net profit for the year | -35,180 | 12,365 | 19,030 |
| Sales revenue net profit margin | -27.05% | 7.89% | 14.16% |